Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
Certara has announced the acquisition of Vyasa Analytics, enhancing its software capabilities with advanced deep-learning technology aimed at the life sciences sector. This acquisition will integrate Vyasa's AI-driven solutions, including the LAYAR data platform, into Certara's biosimulation software, broadening its product offerings and improving decision-making in drug development. Certara serves over 2,000 clients globally, leveraging proprietary software to accelerate drug discovery and development.
- Acquisition of Vyasa will enhance Certara's software capabilities with AI technology.
- Integration of Vyasa's LAYAR platform supports improved decision-making in drug development.
- Expansion of product offerings strengthens Certara's competitive position in the life sciences sector.
- Integration challenges may arise from aligning Vyasa's technology with Certara's existing products.
- Potential difficulties in retaining key personnel from Vyasa post-acquisition.
Certara improves software capabilities by expanding into deep learning and data fabric
PRINCETON, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), today announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software which allows life sciences organizations to perform predictions and answer complex questions across structured and unstructured bio-medical information. The acquisition will elevate Certara’s software by bringing state-of-the-art artificial intelligence (AI) capabilities to its end-to-end platform.
“We are pleased to announce the acquisition of Vyasa, a cutting-edge company that will enhance existing Certara software platforms and further expand our capabilities across our product portfolios,” said William F. Feehery, Chief Executive Officer of Certara. “By incorporating AI into our suite of products, we are building capabilities that will continue to expand our leadership for biosimulation use cases in drug research and development.”
Formed in 2017, Vyasa software provides a novel AI-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. Vyasa’s leading product, LAYAR, a flexible and modular data fabric that evaluates quantitative data, text, and images, offers AI capabilities to support decisions in all phases of drug development.
About Certara
Certara accelerates medicines using proprietary biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries.
Forward Looking Statements
This press release contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about Certara’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. These factors include, but are not limited to: (i) our ability to successfully integrate Vyasa into our existing organization; (ii) our ability to successfully integrate Vyasa products and technology into our existing products; (iii) our ability to retain key personnel from Vyasa or recruit additional qualified personnel; (iv) our ability to achieve operational synergies; (vi) our ability to demonstrate the benefits of combining Vyasa’s technology with our existing or new products and (vii) our ability to satisfy specific customer needs by combining Vyasa’s technology with our existing or new products. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. All information provided in this press release is as of the date of this press release, and Certara undertakes no duty to update such information, except as required under applicable law.
Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com
Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com
FAQ
What is the purpose of Certara's acquisition of Vyasa Analytics?
What is the expected impact of Certara's acquisition of Vyasa on its product offerings?
When did Certara announce the acquisition of Vyasa Analytics?
What technology does Vyasa Analytics bring to Certara?
